InvestorsHub Logo
Followers 4
Posts 211
Boards Moderated 0
Alias Born 02/26/2014

Re: None

Friday, 09/05/2014 9:15:40 AM

Friday, September 05, 2014 9:15:40 AM

Post# of 118382
Roche to buy U.S. biotech firm InterMune for $8.3 billion. $74 per share. 63% premium. Fda has not approved the drug yet. Industry analysts expect the drug, which is given as a pill, to have sales of $1.04 billion in 2019.

Seems to be expensive n there is risk of not getting approval.